A missed assessment may be a simple operational deviation—or it may affect safety, data integrity, and how a study can be interpreted. The difference depends on context.

Modern clinical trial protections were not created in the abstract. Many of the safeguards we now consider fundamental were shaped by tragedies that exposed where research systems had failed patients.

Early oncology development is full of unknowns, and the greatest risks are not always the ones already on the checklist. Strong teams learn to look for what the study may not yet be showing them.

A CTCAE grade gives a toxicity a standardized label, but it cannot capture the full clinical story. Timing, trajectory, reversibility, context, and patient impact can matter just as much as the number.

A dose-limiting toxicity is more than a protocol checkbox. DLT adjudication requires clinical context, pattern recognition, and judgment because one decision can shape the direction of an entire development program.

Medical monitoring is most valuable before a safety signal becomes obvious. This launch issue explores why early recognition, clinical judgment, and proactive oversight matter in early development.